Krystal Biotech Raises Price Target, Reports Revenues

Krystal Biotech reported fiscal Q4 and full-year 2025 results on Feb. 17, revealing VYJUVEK net product revenues of $107.1 million for Q4 and $389.1 million for the year. On Feb. 25 Guggenheim raised its price target to $284 and reiterated a Buy rating; the company said it has secured over 660 US reimbursement approvals, more than 90 prescriptions in Germany, France and Japan, and $955.9 million in cash.